UBE2T and hepatocellular carcinoma: β-catenin is one of the downstream effectors of Akt, and to test whether UBE2T activates β-catenin via Akt, we then treated UBE2T-overexpressing HCC-LM3 cells with Akt inhibitor MK-2206 and siRNA specifically targeting Akt.